ClinicalTrials.gg
CompletedNCT01909869CREDITUpdated Apr 26, 2023

A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions

An interventional study of EXCEL-Ⅱ in Ischemia and Coronary Artery Disease, sponsored by JW Medical Systems Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-26.

Sponsored by JW Medical Systems Ltd (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Ischemia with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Ischemia · China.

Enrollment
30th of 34
45 · median 172
Started
2013
with 3 others
No phase
19 of 39
3 open now
Registered
9th of 39
by date
Lead sponsor
2 of 39
JW Medical Systems Ltd

Among the 39 studies in Ischemia with a site in China, this one is the 30th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2013, is one of 19 with no phase, and was the 9th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

4 of the 39 studies in Ischemia with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Ischemia with a site in China, or all of them as a file.
02

Study summary

One of the purpose of this study is to assess the preliminary safety and feasibility,and to provide related information and evidence for the design of the further pivotal randomized control trial.the other purpose is to assess the performace of the stent delivery system.

Read the detailed description
  1. Single-center, prospective, pilot study
  2. De novo,coronary artery, single vessel and single lesion
  3. Sample size = 45
  4. Follow- up clinical or phone at 1-month,9-month and annually 2 to 5 years
  5. Randomization 2:1 Angio and OCT scheduled follow-up in the hospital
  6. Follow-up Angio and OCT randomized 30 patients for 4-month and 15 patiens for 12-month
03

Conditions studied

  • Ischemia
  • Coronary Artery Disease

Keywords

  • MACE
  • TVR
  • MI
  • TLF
  • Death
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18yrs≤Age≤75yrs .
  2. De novo lesion at native coronary artery.
  3. Single target vessel and single target lesion.
  4. Lesion length ≤32mm.
  5. RVD 2.5mm~4.0mm.
  6. DS%≥70% by visual estimation.
  7. Target lesion could be covered by only one stent.
  8. Subjects are willing to follow the specified requirements follow-up.
  9. A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. is documented by means of a written, signed and dated informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. AMI within one week.
  2. CTO(TIMI0),LM lesion,ostial lesion,graft vessel lesion,bifurcation (side branch RVD≥2.5mm),ISR,mutivessel disease need to be treated.
  3. Severe calcified lesion unable to predilate.
  4. extremely tortuous proximal to the lesion that is inadequate to stent delivery.
  5. ≥Ⅲ or ≤40%.
  6. Prior stenting within 1 year.
  7. Pregnancy or lactation, and plan in postoperative pregnancy or lactation.
  8. Subjects had bleeding tendency or blood coagulation dysfunction or PCI , or anticoagulant therapy taboo or can't continue DAPT healers at least 1 year.
  9. There are other diseases (such as cancer,malignant tumor ,congestive heart failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin, etc.), scheme compliance is poor, interference related data explanation or the limited life (\< 1 year).
  10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent of one of allergy.
  11. Serious liver and kidney function is not complete person.
  12. The investigators think that do not fit to enroll the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    EXCEL-Ⅱ

    A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.

    Device: EXCEL-Ⅱ

Interventions

  • DeviceEXCEL-Ⅱ

    A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions

    Also known as: CREDIT-Ⅰ

06

What researchers measure

Primary outcomes

  1. Primary endpoint(MACE)

    Device oriented cardiovascular endpoint at 30-day (MACE) defined as the composite of Cardiac Death,Myocardial Infarction(Q and non-Q) or Ischemia-driven Target Lesion Revascularization

    Time frame: 30days(MACE)

Secondary outcomes

  1. Secondary endpoint

    In-stent Late Lumen Loss at 4-month and 12-month

    Time frame: 5 years (Follow-up)

07

Study locations

1 site
  • Shenyang Northern Hospital
    Shenyang, Liaoning 110015, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Sep 2013, 8 months.

Of 83 interventional studies with no phase under Ischemia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2013
First posted
Jul 29, 2013
StartActual
Jan 2013
Primary completionActual
Sep 2013
CompletionActual
Jun 4, 2019
Last update
Apr 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01909869
Responsible party
Sponsor
First posted
Jul 29, 2013
Start date
Jan 2013
Primary completion
Sep 2013
Completion
Jun 4, 2019
Last update
Apr 26, 2023

Study contacts

Han y ling, PhD
principal investigator · Shenyang Northern Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion